Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial
Daniel P. Petrylak(Yale University), Siobhan Ng(St John of God Subiaco Hospital), Kim N.(Asian Institute of Technology), Astra M. Liepa(Eli Lilly (United States)), Scott T. Tagawa(Cornell University), Richard A. Walgren(Eli Lilly (United States)), Nobuaki Matsubara(National Cancer Center Hospital East), Sufia Safina(Republican Oncological Clinical Dispensary), B. Yа. Alekseev(P.A. Hertzen Moscow Oncology Research Institute), Sameera R. Wijayawardana(Eli Lilly (United States)), Daniel Castellano(Universidad Complutense de Madrid), Timothy Clay(Duke Medical Center), Ivor Percent(Florida Cancer Specialists & Research Institute), Michiel S. van der Heijden(Zorginstituut Nederland), Syed A. Hussain(University Hospitals Plymouth NHS Trust), Elizabeth Hovey, Jeanny B. Aragon‐Ching(Inova Fairfax Hospital), Rebecca R. Hozak(Eli Lilly (United States)), Ronald de Wit(Erasmus MC Cancer Institute), Aristotelis Bamias(National and Kapodistrian University of Athens), Alexandra Drakaki(University of California, Los Angeles), Giampaolo Tortora(University of Naples Federico II), Xavier García del Muro(Institut Català d'Oncologia), İrfan Çiçin(Istinye University), Wen‐Pin Su(Nanomed (Brazil)), Jae‐Lyun Lee(Ulsan College), Andrey Semenov, Katherine M. Bell‐McGuinn(Memorial Sloan Kettering Cancer Center), Hiroyuki Nishiyama(University of Tsukuba), Hasan Şenol Çoşkun(Akdeniz University), Thomas Powles(Queen Mary University of London), Ulka N. Vaishampayan(University of Michigan), Oday Hamid(Eli Lilly (United States)), Jens Bedke, Suet-Lai Shirley Wong, Georgios Gakis(University Hospital in Halle), Andrea Necchi(Vita-Salute San Raffaele University), Evan Y. Yu(University of Washington), Francesca Russo(Policlinico Umberto I), Alejo Rodríguez‐Vida(Hospital Del Mar), Lajos Géczi(National Institute of Oncology), Marcello Tucci(University of Turin), Hakan Harputluoğlu(Inonu University), Fredrik Laestadius(Centre Oscar Lambret), Thean Hsiang Tan, Yen-Chuan Ou(Tungs' Taichung MetroHarbor Hospital), Annamaria H. Zimmermann(St Bartholomew's Hospital), Aude Fléchon(Institut Català d'Ornitologia), Avivit Peer(Technion – Israel Institute of Technology), Cora N. Sternberg(Cornell University)
Cited by 87
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k